---
title: "Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286245340.md"
description: "On May 13, 2026, in Doylestown, Pennsylvania, Aprea Therapeutics, Inc. (Nasdaq: APRE), a company specializing in precision medicine oncology treatments for cancers with specific biomarkers, announced its financial outcomes for the first quarter of 2026. The quarter concluded on March 31, 2026. They also shared a general overview of their business progress."
datetime: "2026-05-13T10:31:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286245340.md)
  - [en](https://longbridge.com/en/news/286245340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286245340.md)
---

# Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

On May 13, 2026, in Doylestown, Pennsylvania, Aprea Therapeutics, Inc. (Nasdaq: APRE), a company specializing in precision medicine oncology treatments for cancers with specific biomarkers, announced its financial outcomes for the first quarter of 2026. The quarter concluded on March 31, 2026. They also shared a general overview of their business progress.

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Aprea Therapeutics Q1 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/286243183.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)